World's Best Scientists 2026 revealed!

Pauline Brice publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Pauline Brice sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Pauline Brice D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Pauline Brice sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Pauline Brice is affiliated with Hôpital Saint-Louis in France and has contributed extensively to medical research, particularly in the field of medicine. Their publications focus largely on pathology, oncology, and neurology, with additional work in pulmonary and respiratory medicine as well as dermatology.

Their research spans several main topics, including lymphoma diagnosis and treatment, central nervous system (CNS) lymphoma diagnosis and treatment, viral-associated cancers and disorders, cutaneous lymphoproliferative disorders research, lung cancer treatments and mutations, chronic lymphocytic leukemia research, and CAR-T cell therapy research.

Pauline Brice has published frequently in medical journals, with the most common venues being:

  • Blood
  • Haematologica
  • Hematological Oncology
  • Blood Advances
  • Leukemia & lymphoma / Leukemia and lymphoma

Frequent coauthors include:

  • Olivier Casasnovas
  • Hervé Ghesquières
  • Thomas Gastinne
  • Franck Morschhauser
  • Anne-Ségolène Cottereau

Selected recent papers authored by Pauline Brice include:

  • Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study, 2020, Haematologica
  • Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma, 2023, Blood
  • HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma, 2020, Blood
  • Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials, 2020, Cancer Medicine
  • Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up, 2023, Blood Advances

Best Publications

  • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

    Gilles Salles;John Francis Seymour;Fritz Offner;Armando Lopez-Guillermo

  • Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Barbara Pro;Ranjana Advani;Pauline Brice;Nancy L. Bartlett

  • Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

    Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand

  • Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

    P Brice;Y Bastion;E Lepage;N Brousse

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome

    Corinne Haioun;Emmanuel Itti;Alain Rahmouni;Pauline Brice

  • Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

    Corinne Haioun;Eric Lepage;Christian Gisselbrecht;Gilles Salles

  • Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

    Christophe Fermé;Houchingue Eghbali;Jacobus H. Meerwaldt;Chantal Rieux

  • Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

    Gilles Salles;Nicolas Mounier;Sophie de Guibert;Franck Morschhauser

  • Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

    Marc P. E. Andre;Theodore Girinsky;Massimo Federico;Oumedaly Reman

  • Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

    John M M Raemaekers;Marc P E André;Massimo Federico;Theodore Girinsky

  • ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.

    Félix Reyes;Eric Lepage;Gérard Ganem;Thierry J. Molina

  • Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

    C. Haioun;E. Lepage;C. Gisselbrecht;Y. Bastion

  • Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma

    Philippe Solal-Celigny;Eric Lepage;Nicole Brousse;Felix Reyes

  • CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.

    Richard Delarue;Corinne Haioun;Vincent Ribrag;Pauline Brice

  • Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

    Franck Morschhauser;Nathan Fowler;Pierre Feugier;Reda Bouabdallah

  • A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

    Andres Forero-Torres;John P. Leonard;Anas Younes;Joseph D. Rosenblatt

  • Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

    Catherine Sebban;Nicolas Mounier;Nicole Brousse;Coralie Belanger

  • Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

    Robert Chen;Pier Luigi Zinzani;Hun Ju Lee;Philippe Armand

  • Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.

    Y Bastion;J Y Blay;M Divine;P Brice

Frequent Co-Authors

Christian Gisselbrecht
Christian Gisselbrecht Université Paris Cité
Martine Bagot
Martine Bagot Université Paris Cité
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Ali Guermazi
Ali Guermazi Boston University
Céleste Lebbé
Céleste Lebbé Hôpitaux Universitaires Paris-Ouest
Massimo Federico
Massimo Federico University of Modena and Reggio Emilia
Hervé Tilly
Hervé Tilly University of Rouen
Michel Henry-Amar
Michel Henry-Amar Université de Caen Normandie
John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine can open doors to a wide range of rewarding opportunities in healthcare, both at the bedside and beyond. For students who may prefer an alternate route to traditional medical school, several nursing schools that don't require teas or hesi exams make entering the nursing field more accessible. This is ideal for those seeking a faster pathway to a healthcare career.

If your interests lean toward healthcare leadership or management, consider the healthcare administration degrees available online. These programs prepare graduates for pivotal roles in hospitals, clinics, and healthcare organizations.

Registered nurses who are interested in advancing their credentials can look into asn to nurse practitioner programs. These bridge programs help nurses move from an associate degree to a master's degree, allowing for expanded clinical roles and higher earning potential.

Finally, for those passionate about nutrition and wellness, pursuing an online dietitian degree can lead to careers guiding individuals and communities toward healthier lifestyles. Each of these flexible online options aligns well with today’s diverse healthcare landscape and career aspirations.

Best Scientists Citing Pauline Brice

Trending Scientists

Recently Published Articles